{
    "clinical_study": {
        "@rank": "18528", 
        "brief_summary": {
            "textblock": "To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination\n      consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and\n      rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To\n      evaluate the effect of Wobenzym on certain surrogate markers associated with progression of\n      HIV disease."
        }, 
        "brief_title": "The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n        HIV seropositivity with CD4 counts between 250 and 400 cells/mm3.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known hypersensitivity to hydrolytic enzymes such as Wobenzym.\n\n          -  Known sensitivity to lactose.\n\n          -  Presumption that the patient will not comply with the dosing schedule or follow-up\n             appointments.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Concurrent use of immunosuppressive therapy or steroids."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002311", 
            "org_study_id": "122A"
        }, 
        "intervention": {
            "intervention_name": "Wobenzym", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Wobenzym"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Wobenzym", 
            "Hydrolases"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10019"
                }, 
                "name": "Saint Luke's - Roosevelt Hosp Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I-II Dose Escalation Study to Examine the Safety of Four Doses of Wobenzym in HIV Seropositive Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002311"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mucos Pharma GmbH and Co", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1993"
    }, 
    "geocoordinates": {
        "Saint Luke's - Roosevelt Hosp Ctr": "40.714 -74.006"
    }
}